Gustave Roussy immune score is an independent prognostic factor for treatment response and survival in advanced non-small cell lung cancer treated with nivolumab at second-line therapy
Oncology in Clinical Practice · 2025
DOI: 10.5603/ocp.101103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology in Clinical Practice, 2025. Verfasst von Ahmet Kucukarda und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kucukarda, A., Gulbagci, B., & Yuce, E. (2025). Gustave Roussy immune score is an independent prognostic factor for treatment response and survival in advanced non-small cell lung cancer treated with nivolumab at second-line therapy. Oncology in Clinical Practice. https://doi.org/10.5603/ocp.101103
Vancouver
Kucukarda A, Gulbagci B, Yuce E. Gustave Roussy immune score is an independent prognostic factor for treatment response and survival in advanced non-small cell lung cancer treated with nivolumab at second-line therapy. Oncology in Clinical Practice. 2025. doi:10.5603/ocp.101103
BibTeX
@article{Kucukarda2025,
author = {Kucukarda, Ahmet and Gulbagci, Burcu and Yuce, Elif},
title = {Gustave Roussy immune score is an independent prognostic factor for treatment response and survival in advanced non-small cell lung cancer treated with nivolumab at second-line therapy},
journal = {Oncology in Clinical Practice},
year = {2025},
doi = {10.5603/ocp.101103}
}
EUVIMED